Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03834337
Other study ID # TOPANA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2019
Est. completion date January 31, 2022

Study information

Verified date November 2023
Source Technical University of Munich
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This multi-centre prospective cohort study of symptomatic patients with active neurocysticercosis (NCC) aims to identify factors related to treatment success of anthelmintic therapy. Neurological symptom/sign and cyst resolution, quality of life, accuracy and performance of serological T. solium diagnostics and NCC-specific immunological parameter will be followed up at multiple time points in the study. The final assessment will be done six months after the end of anthelmintic treatment. This study aims to guide treatment of NCC in sub-Saharan Africa by identifying factors that are associated with treatment outcomes. The factors that cause some people to fail complete resolution of all cysts and/or symptoms/signs are unknown.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date January 31, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group 10 Years and older
Eligibility Inclusion Criteria: - All patients will be included who - Meet the definitions of active NCC - Have epilepsy, epileptic seizures or chronic/severe progressive headaches - Are physically and mentally fit enough for treatment - Are willing to be hospitalized and to receive the standard treatment for NCC - Are willing to participate a follow-up for six months - Are willing and able to consent to this study, with consent recorded on a signed consent form Exclusion Criteria: - Potential participants who will not meet the above inclusion criteria will be excluded. - Women who are pregnant will not be included, but re-evaluated for inclusion into the study after they have given birth. - Potential participants who are currently taking or have taken albendazole, praziquantel, or a corticosteroid within the past 12 months will be excluded. - People with uncontrolled hypertension and/or diabetes will be excluded from the study but will be re-evaluated for inclusion once their hypertension and/or diabetes have been treated. - People with chronic consuming illness such as cancer and those with mental handicap severe enough to not allow them to follow the study instructions or reliably take their medication will be excluded. - Children aged <10 years.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Tanzania National Institute of Medical Research Dar Es Salaam

Sponsors (4)

Lead Sponsor Collaborator
Technical University of Munich National Institute for Medical Research, Tanzania, Sokoine University of Agriculture, University of Zambia

Country where clinical trial is conducted

Tanzania, 

References & Publications (1)

Stelzle D, Makasi C, Schmidt V, Trevisan C, Van Damme I, Ruether C, Dorny P, Magnussen P, Zulu G, Mwape KE, Bottieau E, Prazeres da Costa C, Prodjinotho UF, Carabin H, Jackson E, Fleury A, Gabriel S, Ngowi BJ, Winkler AS. Efficacy and safety of antiparasi — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Resolution of lesions The number of active cysts identified by CT scan after treatment Change in number of active cysts from before treatment to six months after treatment termination
Primary Symptom/sign frequency The percentage of participants who exhibit a neurological symptom/sign of NCC: chronic/severe progressive headache or epileptic seizures. Change of symptom/sign frequency from before treatment to six months after treatment termination
Secondary Health-related Quality of Life (all patients): WHOQOL-Bref questionnaire The change in participants' self-reported quality of life from before to after treatment, as measured by the WHOQOL-Bref questionnaire (in all participants) [World Health Organization Quality of Life questionnaire; consisting of 26 items].
Quality of life is assessed by four domains - physical health, psychological, social relationships and environment. In each domain a score of 0 to 100 can be achieved. Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life). Domains are not summarised to an overall score.
Change in quality of life from before treatment to six months after treatment termination
Secondary Health-related Quality of Life (epileptic patients) The change in participants' self-reported quality of life from before to after treatment, as measured by the QOLIE-31 questionnaire [Quality of life in epilepsy - 31 items].
The score consists of 7 domains which all are range from 0 to 100%. Those domains are: seizure worry, overall quality of life, emotional well-being, energy/fatigue, cognitive, medication effects, social function. The seven domains are then summarized to an overall score by applying weights to each category. The overall score ranges from 0 to 100% with 100% being best possible quality of life.
Change in quality of life from before treatment to six months after treatment termination
Secondary Change in presence of T.solium-specific antigen Change in presence of T.solium-specific antigen in the blood of patients with active neurocysticercosis Change in presence of T.solium-specific antigen from before treatment to six months after treatment termination
See also
  Status Clinical Trial Phase
Completed NCT00527579 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB Phase 1
Completed NCT00526916 - PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28 Phase 1
Terminated NCT02233855 - People Presenting With Neurocysticercosis in North America
Recruiting NCT00001205 - Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Completed NCT02234570 - Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole Phase 1
Terminated NCT02947581 - Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO) Phase 3
Completed NCT02243644 - Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Phase 3
Not yet recruiting NCT06376396 - Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis Phase 4
Completed NCT03874689 - Investigation of Environmental Factors Associated With Transmission of T. Solium in Endemic Villages of Zambia
Completed NCT00441285 - Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ) Phase 2/Phase 3
Not yet recruiting NCT04706819 - Parenchymal and Extraparenchymal Neurocysticercosis-A Registry Based Study
Completed NCT00283699 - A Pilot Study of Neurocysticercosis Treatment Phase 3
Terminated NCT02945527 - Treatment of Peri-calcification Edema in Neurocysticercosis (NCC) Phase 2/Phase 3
Completed NCT00290823 - Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients Phase 3
Completed NCT03851419 - The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania